|
The American Society Of Clinical Oncology 2004 Annual Meeting was held June 4-7, 2004, in New Orleans, Louisiana. The IMF is grateful to the investigators and presentors who contributed their time to provide this update and hopes that you will find it informative and useful. To get started, first select a speaker from the list below, then: - Click on the document icon to view/download a PDF
- Click on the camera icon to view the video.
- Scroll down to read the presentation online.
|
|
|
|
|
Bortezomib {Velcade®} vs. dexamethasone in relapsed multiple myeloma: A phase 3 randomized study |
|
|
|
|
A randomised phase III trial of thalidomide {Thalomid®}plus dexamethasone versus dexamethasone in newly diagnosed multiple myeloma (E1A00): A trial coordinated by the Eastern Cooperative Oncology Group |
|
|
|
|
PAD therapy (bortezomib{Velcade®}, doxorubicin and dexamethasone) for untreated multiple myeloma (MM) |
|
|
|
|
Myeloma Treatments, First-line therapy with bortezomib (formerly PS-341) {Velcade®} in patients with multiple myeloma (MM) |
|
|
|
|
A phase I/II study of Xcellerated T Cells after autologous peripheral blood stem cell transplantation in patients with multiple myeloma |
|
|
|
|
Update of the 166Ho-DOTMP transplant studies in multiple myeloma as well as a discussion of the randomized study for patients with refractory MM |
|
|
|
|
Oral melphalan, prednisone, and thalidomide for newly diagnosed myeloma patients. |
|
|
|
|
Final Results: Multicenter Trial of DVd vs VAd in Newly Diagnosed Multiple Myeloma |
|
|
|
|
Cost Effectiveness of Pegylated liposomal doxorubicin (DOXIL®/CAELYX®) vs. doxorubicin in the VAd regimen (DVd) to treat multiple myeloma |
|
|
|
|
Leading experts discuss current perspectives on front line therapy for newly-diagnosed myeloma patients |
|
|
back
print
back to top